Avience Biomedicals IPO
GMP, Subscription, Price, Dates & Financial Details
Medical Equipment
Incorporated in June 2024, Avience Biomedicals Limited is an ISO-certified company engaged in the manufacturing, supply, export, distribution, and trading of advanced molecular diagnostic solutions. The company operates in the fields of biotechnology, genomics, and the In-Vitro Diagnostics (IVD)…
Open Date
Thu, 18 Jun 2026
Close Date
Mon, 22 Jun 2026
Price Band
₹ 196 – 208
Lot Size
600
Issue Size
₹ 30.00 Cr
Minimum Investment
₹ 249,600 (1200 Shares)
Grey Market Premium Analysis
Day Wise GMP→Unofficial premium quoted in the grey market, tracked daily against the price band cap.
Grey market trading is unregulated. GMP figures are indicative only and should not be the sole basis for investment decisions - treat as a sentiment indicator, not a guarantee.
IPO Details
Avience Biomedicals IPO has successfully completed its IPO process and is now listed on NSE SME Platform. According to the Red Herring Prospectus (RHP), the IPO was a book-built issue with a total issue size of ₹30 Crore, comprising a fresh issue of 13.72 Lakh equity shares aggregating to ₹29.00 Crore.
The Avience Biomedicals IPO remained open for subscription from June 18, 2026, to June 22, 2026. The basis of allotment was finalized on June 23, 2026, and the company's shares were listed on NSE SME Platform on June 25, 2026.
The company had fixed the price band at ₹196 to ₹208 per share, with a lot size of 600 shares. Retail investors were required to make a minimum investment of ₹249,600 (based on the upper price band) to apply for one lot.
Skyline Financial Services Private Ltd served as the registrar to the issue. Fintellectual Corporate Advisors Private Limited acted as the Book Running Lead Managers (BRLMs) to the issue.
With the successful completion of the IPO process, Avience Biomedicals Limited is now a publicly listed company on NSE SME Platform. Investors can track the company's share price, trading performance, financial results, and corporate announcements through the stock exchanges.
Avience Biomedicals IPO Timeline (Tentative)
- IPO Open Date
- Thu, 18 Jun 26
- IPO Close Date
- Mon, 22 Jun 26
- Basis of Allotment
- Tue, 23 Jun 26
- Initiation of Refunds
- Wed, 24 Jun 26
- Credit of Shares to Demat
- Wed, 24 Jun 26
- Listing Date
- Thu, 25 Jun 26 — NSE & BSE
Open Date
18 June 2026
Close Date
22 June 2026
Basis Of Allotment
23 June 2026
Listing Date
25 June 2026
IPO Subscription
Check Live Subscription →The Avience Biomedicals IPO has received bids for 37,06,80,000 shares against 9,61,800 shares offered, resulting in an overall subscription of 385.4x. the NII category is subscribed 597.63x, Retail Investors 401.36x, and QIBs 196.77x. Within the NII category, BNII is subscribed 670.77x, while SNII is subscribed 451.35x.
QIB
196.77x
NII
597.63x
BNII
670.77x
SNII
451.35x
RII
401.36x
Total
385.4x
IPO Reservations
The Retail Individual Investor (RII) category has the highest allocation with 4,81,200 shares, representing 50.03% of the total issue. Qualified Institutional Buyers (QIBs) are allocated 2,73,600 shares (28.45%), while Non-Institutional Investors (NIIs) receive 2,07,000 shares (21.52%).
| Category | Shares Offered | Shares Offered |
|---|---|---|
| Qualified Institutions | 273,600 | 28.45% |
| Non-Institutional | 207,000 | 21.52% |
| BNII | 138,000 | 14.35% |
| SNII | 69,000 | 7.17% |
| Retail Investors | 481,200 | 50.03% |
| Total | 961,800 | 100% |
Financials Details(₹ in Crores)
| Particular | 31 Jan 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 51.96 | 43.6 | 25.63 |
| Revenue | 28.85 | 29.54 | 16.64 |
| Profit After Tax | 4.18 | 5.14 | 1.98 |
| Net Worth | 24.7 | 20.52 | 6.05 |
| Reserve & Surplus | 20.67 | 16.49 | 2.77 |
| Total Borrowings | 17.17 | 13.75 | 7.73 |
Financials Performance
Performance Indicators
EPS Pre
Earnings per share before the IPO.
P/E Pre
IPO Offer Price ÷ EPS Pre.
EPS Post
Expected earnings per share after the IPO..
P/E (Post Issue)
IPO Offer Price ÷ EPS Post.
Avience Biomedicals Limited KPI Information
| Particular | Jan 2026 | Mar 2025 | Mar 2024 |
|---|---|---|---|
| ROE % | 18.49 | 38.64 | 39.19 |
| ROCE % | 15.16 | 21.68 | 22.2 |
| Debt / Equity | 0.69 | 0.67 | 1.28 |
| RoNW % | 18.49 | 38.64 | 39.19 |
| Pat Margin % | 0 | 15.86 | 8.83 |
Peers Comparison
No Peer Comparision Available
About Avience Biomedicals Limited
Incorporated in June 2024, Avience Biomedicals Limited is an ISO-certified company engaged in the manufacturing, supply, export, distribution, and trading of advanced molecular diagnostic solutions. The company operates in the fields of biotechnology, genomics, and the In-Vitro Diagnostics (IVD) industry, serving a wide range of healthcare and research institutions.
The company has significantly expanded its product portfolio from IVD rapid test kits to a comprehensive range of diagnostic and medical devices. Its offerings cater primarily to the B2B (Business-to-Business) and B2G (Business-to-Government) segments, reflecting its commitment to addressing diverse healthcare and diagnostic requirements.
Avience Biomedicals Limited serves Pathology Laboratories, Microbiology Laboratories, Hospitals, Diagnostic Centers, Research Institutions, and Government Healthcare Organizations across India and international markets.
The company’s state-of-the-art manufacturing facility is located in Noida, Uttar Pradesh, enabling efficient production and quality control of its healthcare products.
Product Portfolio
1. Rapid Diagnostic Test Kits
- AVISURE Dengue Combo Test
- Malaria Rapid Test (Pf/Pv)
- AVISURE Syphilis Rapid Test
- Other infectious disease diagnostic kits
2. Biochemistry Analyzers and Reagents
- BS-240 Fully Automatic Biochemistry Analyzer
- AVIENBIO Albumin Kit
- Various clinical chemistry reagents and consumables
3. Molecular Diagnostic Solutions
- COVID-19 Hid RT-qPCR Assay
- Molecular testing kits for infectious disease detection
- Advanced genomics and PCR-based diagnostic products
4. Hematology Analyzers
- BC-20s 3-Part Hematology Analyzer
- Hematology testing systems and related consumables
5. Medical Devices
- Oxy-5 Oxygen Concentrator
- Oxy-10 Oxygen Concentrator
- Viral Transport Medium (VTM)
- Other healthcare and diagnostic equipment
In addition to its manufacturing operations, the company actively engages in the distribution and trading of medical equipment and diagnostic devices, strengthening its presence across the healthcare value chain.
Human Resources
As of January 31, 2026, Avience Biomedicals Limited employed 75 permanent employees and 33 contractual employees, reflecting its growing operational capabilities and commitment to supporting its expanding business activities.
With a focus on quality, innovation, and customer-centric healthcare solutions, Avience Biomedicals Limited continues to strengthen its position in the biotechnology, diagnostics, and medical devices sectors, both in India and international markets.
Avience Biomedicals IPO Promoters
- Mr. Dharam Deo Choudhary
- Mr. Ram Nagina Choudhary
- Mr. Janardan Pal
- Ms. Deepa Choudhary
Promoters Holding
Holding Pre Issue
87.89%
Holding Post Issue
64.59%
Avience Biomedicals IPO Objective
The Company Avience Biomedicals IPO proposes to utilise the Net Proceeds from the Issue towards the following objects.
- Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh.
- Funding the working capital requirement of our Company
- General Corporate Purpose
Avience Biomedicals Limited Address / Contact Details
Avience Biomedicals Ltd.
C-11, Block-C,Community Centre,
Janakpuri A-3,Delhi, New Delhi, 110058
Phone: 1800-12-04-636
Email: info@avienbio.com
Website: https://avienbio.com/
IPO Snapshot
Avience Biomedicals IPO Lot Size
The Avience Biomedicals IPO has a lot size of 600 shares. Retail investors require a minimum investment of ₹2,49,600 by applying for 2 lot (1,200 shares). The maximum application allowed for the retail category is 2 lots (1,200 shares), requiring an investment of ₹2,49,600.
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 2 | 1,200 | 249,600.00 |
| Retail (Max) | 2 | 1,200 | 249,600.00 |
| S-HNI (Min) | 3 | 1,800 | 374,400.00 |
| S-HNI (Max) | 8 | 4,800 | 998,400.00 |
| B-HNI (Min) | 9 | 5,400 | 1,123,200.00 |
Issue Reservation
- QIB — 28.45%
- NII — 21.52%
- RII — 50.03%
Book Running Lead Managers
- Fintellectual Corporate Advisors Private Limited
IPO Documents & Links
Explore More IPOs
Currently Open
Coming Up Next
Disclaimer: This data is for informational purposes only and does not constitute investment advice.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
What is the Avience Biomedicals IPO?
Avience Biomedicals IPO is a Book-building IPO with a total issue size of ₹30 crore. The Avience Biomedicals IPO price band is ₹196 to 208 per share. The Avience Biomedicals IPO subscription opens on Thu, Jun 18, 2026, and closes on Mon, Jun 22, 2026. The Avience Biomedicals IPO will be listed on the NSE. Skyline Financial Services Private Ltd is the registrar for the Avience Biomedicals IPO.
When will the Avience Biomedicals IPO open for subscription?
The Avience Biomedicals IPO opens on Thu, Jun 18, 2026 and closes on Mon, Jun 22, 2026
What is Avience Biomedicals IPO Price Band?
Avience Biomedicals IPO Price Band is ₹196 to 208 per share.
What is Avience Biomedicals IPO Lot Size?
Avience Biomedicals IPO lot size is 600 shares, Retail investors need a minimum investment of ₹249600 based on the upper price band
What is the minimum investment for Avience Biomedicals IPO?
The minimum investment for Avience Biomedicals IPO is ₹249600, based on one lot of 600 shares at the upper price band of ₹208 per share.
How to apply for Avience Biomedicals IPO?
Investors can apply for the Avience Biomedicals IPO through the ASBA (Application Supported by Blocked Amount) facility offered by their bank or through UPI using a SEBI-registered broker or trading app. Select the desired lot size, enter your bid within the price band, and submit the application before Mon, Jun 22, 2026. The application amount remains blocked until the Avience Biomedicals IPO allotment is finalized.
What is Avience Biomedicals IPO Issue Size?
Avience Biomedicals IPO issue size is ₹30 crores.
What is the Avience Biomedicals IPO Allotment Date?
Avience Biomedicals IPO allotment date is Tue, Jun 23, 2026.
Who is the Avience Biomedicals IPO Registrar?
The registrar for Avience Biomedicals IPO is Skyline Financial Services Private Ltd. Investors can go to Skyline Financial Services Private Ltd website to check Avience Biomedicals IPO allotment status, refund processing, and other IPO-related information.
What is the Avience Biomedicals IPO GMP?
The Avience Biomedicals IPO GMP (Grey Market Premium) is ₹85 as of Thu, Jun 18, 2026. Based on the upper price band of ₹208 per share, the estimated Avience Biomedicals IPO listing price is ₹293, indicating a potential listing gain of approximately 40.87% over the issue price.
Who is the Avience Biomedicals IPO Lead Manager?
The book-running lead managers (BRLMs) for the Avience Biomedicals IPO are . The lead managers are responsible for managing the IPO process, including issue structuring, regulatory compliance, marketing the public issue, coordinating with investors, and ensuring a smooth listing process. For complete details, investors should refer to the Avience Biomedicals IPO Red Herring Prospectus (RHP).